GP IIb / IIIa Blockade in Elective Percutaneous Coronary Intervention

Dery, J. P.; Harrington, R. A.; Tcheng, J. E.
February 2004
Current Pharmaceutical Design;Feb2004, Vol. 10 Issue 4, p387
Academic Journal
Cumulative scientific evidence gathered over the past ten years has confirmed the role of platelet GP IIb / IIIa inhibitors in reducing ischemic complications of patients undergoing percutaneous coronary intervention (PCI). Recently, mortality data available on more than 20,000 patients enrolled in randomized clinical trials suggest that GP IIb / IIIa blockade also improves short and long-term survival after PCI. Despite convincing arguments, GP IIb / IIIa inhibitors are still inconsistently administered in patients undergoing coronary intervention. The following review will discuss the scientific grounds and the principal controversies surrounding the use of these compounds in patients undergoing elective percutaneous coronary intervention.


Related Articles

  • Direct thrombin inhibitor urged for PCI patients. Fernandez, Julio // Drug Topics;1/23/2006, Vol. 150 Issue 2, p14 

    The article reports that percutaneous coronary intervention (PCI) comprises a variety of procedures that are used to diagnose patients with coronary artery syndromes such as heart attacks and angina. Reportedly, more than one million PCI procedures are performed annually in the U.S. and it is...

  • Less bleeding with fondaparinux in ACS.  // Formulary;Oct2005, Vol. 40 Issue 10, p344 

    Reports that the factor Xa inhibitor fondaparinux prevents death, myocardial infarction and refractory ischemia at nine days as well as low-molecular-weight heparin enoxaparin in patients with acute coronary syndromes (ACS), while reducing the incidence of bleeding. Improvement in survival;...

  • Treatment of stable angina. Luscher, Thomas F. // BMJ: British Medical Journal (International Edition);07/08/2000, Vol. 321 Issue 7253, p62 

    Editorial. Discusses a study, published in the July 8, 2000 issue of the 'British Medical Journal,' comparing percutaneous transluminal coronary angioplasty and medical treatment for non-acute coronary artery disease. Effectiveness of surgery and drug treatments; Details of clinical trials...

  • Pharma Developments.  // Cardiovascular Devices & Drugs;Dec2008, Vol. 14 Issue 12, p18 

    The article reports on the completion of enrollment by Regado Biosciences for its Phase IIa study of REG1 anticoagulation system in patients undergoing elective percutaneous coronary intervention. The study will assess whether REG1 can replace standard heparin therapy during the performance of...

  • Adjunctive streptokinase offers no benefit to PTCA for acute MI.  // Geriatrics;Jun1993, Vol. 48 Issue 6, p75 

    The article reports that patients who undergo percutaneous transluminal coronary angioplasty (PTCA) for acute myocardial infarction (MI) derive no extra benefit from the routine adjunctive use of IV streptokinase, The finding was reported by the authors of a small, prospective,...

  • Diagnostic value of plasma fibronectin level in predicting the presence and severity of coronary artery disease. Ozcelik, Fatih; Erdogan, Okan; Aktoz, Meryem; Ekuklu, Galip; Tatli, Ersan; Demir, Muzaffer // Annals of Hematology;Mar2009, Vol. 88 Issue 3, p249 

    The relation between fibronectin and coronary artery disease (CAD) according to previous study results is controversial. The aim of the present study is to investigate the predictive value of fibronectin in determining the presence and severity of CAD. Patients with stable angina ( n = 62) who...

  • CABG COMPARED WITH PTCA HEART DISEASE. Runyan, Sue; Dobie, Sharon // Journal of Family Practice;Feb1998, Vol. 46 Issue 2, p112 

    The article discusses research being done on the use of coronary artery bypass grafting and percutaneous transluminal coronary angioplasty (PTCA) in cases of myocardial infarction and cardiac disease, with reference to a study by B. R. Chaitman, A. D. Rosen, D. O. Williams et al, which appeared...

  • Studies: Immediate PTCA is preferred for high-risk MI patients.  // Geriatrics;Jun1993, Vol. 48 Issue 6, p23 

    The article cites several studies about the treatment of acute myocardial infarction (MI). Two new studies strongly support the use of immediate precutaneous transluminal coronary angioplasty (PTCA) over thrombolytic therapy for patients with acute MI. However, a third study suggests that the...

  • Diagnostic performance of transluminal attenuation gradient and fractional flow reserve by coronary computed tomographic angiography (FFR) compared to invasive FFR: a sub-group analysis from the DISCOVER-FLOW and DeFACTO studies. Nakanishi, Rine; Matsumoto, Suguru; Alani, Anas; Li, Dong; Kitslaar, Pieter; Broersen, Alexander; Koo, Bon-Kwon; Min, James; Budoff, Matthew // International Journal of Cardiovascular Imaging;Aug2015, Vol. 31 Issue 6, p1251 

    Although coronary computed tomographic angiography (CCTA) has been a robust diagnostic tool to identify anatomical significance of coronary artery disease (CAD), the utility of CCTA to assess hemodynamic significance of CAD remains unclear. We investigated the diagnostic performance of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics